1. Home
  2. CGEM vs FINV Comparison

CGEM vs FINV Comparison

Compare CGEM & FINV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$20.59

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo FinVolution Group

FINV

FinVolution Group

N/A

Current Price

$4.37

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CGEM
FINV
Founded
2016
2007
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
CGEM
FINV
Price
$20.59
$4.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
1
Target Price
$30.13
$12.10
AVG Volume (30 Days)
576.3K
391.7K
Earning Date
05-11-2026
05-19-2026
Dividend Yield
N/A
6.09%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.20
$10.58
P/E Ratio
N/A
$3.87
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$4.35
52 Week High
$21.00
$9.73

Technical Indicators

Market Signals
Indicator
CGEM
FINV
Relative Strength Index (RSI) 72.03 31.51
Support Level $16.40 N/A
Resistance Level N/A $5.07
Average True Range (ATR) 1.18 0.14
MACD 0.31 -0.06
Stochastic Oscillator 96.18 1.23

Price Performance

Historical Comparison
CGEM
FINV

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About FINV FinVolution Group

FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.

Share on Social Networks: